

Rebuild bone.
Rebuild it with TYMLOS.
Change the trajectory of osteoporosis for your patients.1
How TYMLOS rebuilds bone.1
TYMLOS acts quickly to shift the balance during bone remodeling to favor bone formation.1-4
TYMLOS is a PTHrP(1–34) analog that acts as an agonist at the PTH1 receptor. It activates the cAMP signaling pathway, which triggers the remodeling process in favor of bone formation.1,5-8
formation in open-label study
Watch the video to learn about abaloparatide's mechanism of action.1
Video is intended to be viewed on desktop. If viewing on a mobile device, video should be played in full screen landscape mode.
TYMLOS stimulates early increases in bone formation markers that remain elevated for the duration of therapy.1




Mineralizing surface increase at 3 months†2

Mechanism of action representations are not meant to imply clinical efficacy. No new safety signals were seen. Adverse events were similar to those seen in the ACTIVE trial.1,2
†3 months is the amount of time it takes bones to form and mineralize in healthy adults.2-4
Open-label study evaluating the effects of TYMLOS on indices of bone formation.2
STUDY DESIGN: Open-label, single-arm study that evaluated the effects of TYMLOS on indices of bone formation using transiliac bone biopsies in postmenopausal women with osteoporosis. 23 biopsies were included in the safety population; 19 biopsies were evaluable. Subjects received double fluorochrome labels before treatment and before biopsy collection at 3 months.
PRIMARY ENDPOINT: Change in the mineralizing surface per unit of bone surface (MS/BS) in trabecular bone, from baseline to 3 months.
SECONDARY ENDPOINTS:
- MS/BS across cortical and periosteal surfaces2
- Remodeling- and modeling-based bone formation2
INCLUSION CRITERIA:
- Postmenopausal women with osteoporosis, aged 50-85 years2
- BMD: T-score ≥-2.5 at the lumbar spine or hip (including femoral neck or total hip) OR BMD+Fracture History: T-score ≥-2.0 at the lumbar spine or hip and a recent (>5 years) low-trauma vertebral, forearm, humerus, sacral, pelvic, femoral, or tibial fracture2
EXCLUSION CRITERIA: Patients with unevaluable lumbar spine or hip BMD, a history of bone disorders, metabolic bone disease, malabsorption, cancer in the past 5 years, osteosarcoma at any time, or prior radiotherapy (besides radioiodine) were excluded. Patients with a known hypersensitivity to TYMLOS, those who received prior treatment with PTH or PTHrP, denosumab, or IV bisphosphonates, took medications that interfere with bone metabolism within 6 months, or received treatment with oral bisphosphonates within 3 years were not eligible for this study.2
STUDY LIMITATIONS2:
- Consider open-label study limitations when interpreting results. This open-label study was not blinded. These results are not meant to imply fracture efficacy
- Single-arm study with no placebo group comparison and included only Caucasian female participants
- Since the study had no control arm, a quadruple labeling procedure was used for internal control, allowing for a baseline comparison of bone formation indices within the same sample
- Data generated from bone biopsies are variable, between subjects, and between biopsies taken from the same subject
- While significant changes in these parameters are unlikely after 3 months of treatment, this labeling procedure does limit the ability to evaluate the effect of treatment on bone microarchitectural endpoints
- Transiliac bone biopsies may not precisely reflect changes in bone at weight-bearing sites
BMD=bone mineral density; cAMP=cyclic adenosine monophosphate; IV=intravenous; PTH1=parathyroid hormone 1; PTHrP=parathyroid hormone-related peptide; s-CTX=serum carboxy-terminal cross-linked telopeptide of type 1 collagen; s-P1NP=serum procollagen type 1 N-terminal propeptide.
Could your patients be at imminent risk for fracture?

HAVE A T-SCORE
OF -3.0 OR WORSE9
CONTINUE TO LOSE BONE ON BISPHOSPHONATES9-11
Patients may continue to lose bone mass and are at risk for fracture despite bisphosphonate therapy.10-11
IN WOMEN
According to a retrospective study of 7,435 women ≥50 years of age and adherent to oral bisphosphonates for ≥2 years11:
35%HAD A FRACTURE, DECREASING BMD, OR A LOW POSTTREATMENT T-SCORE ≤-2.511
Patients may continue to lose bone mass and are at risk for fracture despite bisphosphonate therapy.10-11
IN WOMEN
According to a retrospective study of 7,435 women ≥50 years of age and adherent to oral bisphosphonates for ≥2 years11:
35%HAD A FRACTURE, DECREASING BMD, OR A LOW POST TREATMENT T-SCORE ≤-2.511
Worsening BMD predicts risk for fracture.3
BMD and fracture risk show an overlapping trend in both males and females—for each point reduction in the T-score, the risk of fracture roughly doubles.12-14


Using TYMLOS as initial therapy for patients at high risk for fracture.1,9
The 2020 AACE Guidelines support the use of TYMLOS* as initial therapy for appropriate patients, such as those outlined above.1,9
AACE/ACE=American Association of Clinical Endocrinologists/American College of Endocrinology; BMD=bone mineral density; FRAX=fracture risk assessment tool.

See how TYMLOS performed in clinical trials.1
